Gilead Sciences

liver disease fibrosis NASH NAFLD cancer cirrhosis liver
Biotech

Zydus' phase 3 win tees up filing to challenge Gilead and Ipsen

The win in primary biliary cholangitis clears the path to an FDA filing to establish the company as a challenger to Gilead, Intercept and Ipsen.
Nick Paul Taylor Aug 29, 2025 10:59am
Dried up river bed

Cell therapy biotech Appia shuts down as funding runs dry

Aug 25, 2025 5:55pm
rainbow kite flying in the sky

Kite sails into in vivo CAR-T space via $350M Interius buyout

Aug 21, 2025 9:59am
Person throwing piece of paper into full waste bin

Gilead culls last MASH program, 2 cancer assets

Aug 8, 2025 11:50am
Return To Sender stamp on an envelope

Gilead hands back one Arcus cancer candidate from $725M deal

Aug 7, 2025 6:35am
Uninhabited island full of trees

Galapagos builds island of cell therapies amid pipeline pruning

Jul 24, 2025 10:59am